Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference

Core Points - VolitionRx Limited will participate in the 97th Annual Western Veterinary Conference (WVC) from March 2-5, 2025, in Las Vegas, NV, attracting approximately 20,000 veterinary professionals [1][5] - The company will showcase its Nu.Q® Vet Cancer Test, which aids in the detection of seven common cancers in dogs, emphasizing its accessibility, affordability, and ease of use [3][4] - Volition's strategic commercialization efforts in North America aim to expand awareness and education regarding the Nu.Q® Vet Cancer Test [3] Event Details - Presentation 1: "Detect, Treat, Monitor: Navigating the Canine Cancer Journey with Nu.Q® Vet Cancer Test" by Dr. Sue Ettinger on March 3, 2025, from 2:00 PM to 2:50 PM [4] - Presentation 2: "Utilizing the Nu.Q® Vet Cancer Test in Practice" by Dr. Brett Cordes on March 4, 2025, from 10:30 AM to 11:00 AM [4] - Presentation 3: "The Nu.Q® Vet Cancer Test - Early Detection with Canine Cancer Screening" by Dr. Tom Butera on March 5, 2025, from 12:10 PM to 1:00 PM [4] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring [5][6] - The company is developing cost-effective blood tests to diagnose and monitor various diseases, including cancers and conditions associated with NETosis, such as sepsis [6][7] - Volition's research and development activities are centered in Belgium, with additional facilities in the U.S. and London [7]